Mar 22, 2022 / 05:30PM GMT
Matthew Ian Mishan - KeyBanc Capital Markets Inc., Research Division - VP & Senior Equity Research Analyst
Good afternoon. I'd like to welcome everyone to the first day of the KeyBank Life Sciences MedTech & Investor Forum. My name is Matt Mishan. I'm a senior at MedTech Analyst, and I'm pleased to be joined by ResMed, which is represented today by its CEO, Mick Farrell.
Questions and Answers:
Matthew Ian Mishan - KeyBanc Capital Markets Inc., Research Division - VP & Senior Equity Research AnalystFor the audience, I'll start us off, but questions can be submitted directly to me by typing into the box below the video screen, and I can relay.
So Mick, welcome. Thank you for joining us. I'm just going to get right to it and ask how should we think about the Russia-Ukraine and the COVID shutdowns in Asia impacting your ability to kind of ramp supply chain at this point?
Michael J. Farrell - ResMed Inc. - CEO & Director
Yes. Well, look, there are a bunch of factors in the market right now,